Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4908743 | 0.95 | MAPT (0.51) | MAPTALDH1A1KMT2ATLR8TSHR | |
| SCHEMBL4899064 | 0.79 | KDM4E (0.55) | MAPTALDH1A1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5616111 | 0.78 | TLR8 (0.37) | MAPTALDH1A1KMT2ATLR8SMN1; SMN2 | |
| SCHEMBL27700936 | 0.76 | TLR8 (0.53) | MAPTALDH1A1KMT2ATLR8SMN1; SMN2 | |
| SCHEMBL27925787 | 0.74 | TLR8 (0.54) | MAPTALDH1A1KMT2ATLR8SMN1; SMN2 | |
| SCHEMBL27849754 | 0.74 | TLR8 (0.54) | MAPTALDH1A1KMT2ATLR8SMN1; SMN2 | |
| SCHEMBL27700941 | 0.74 | TLR8 (0.54) | MAPTALDH1A1KMT2ATLR8SMN1; SMN2 | |
| SCHEMBL11669834 | 0.74 | LMNA (0.57) | MAPTKMT2ATLR8TDP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL28836326 | 0.73 | TLR8 (0.55) | MAPTALDH1A1KMT2ATLR8SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27943012 | 0.73 | TLR8 (0.55) | MAPTALDH1A1KMT2ATLR8SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| CN-101056631-A | Derivatives of aryl (or heteroaryl) azolylcarbinols (in particular cizolirtin citrate) for the treatment of opioid addiction | ESTEVE LABOR DR (ES) | 2007-10-17 | — | — | CN | claimed |
| CN-101031291-A | Compound containing methanol and composition containing at least one nsaid active substance | ESTEVE LABOR DR (ES) | 2007-09-05 | — | — | CN | claimed |
| CN-1976722-A | Active substance combination | ESTEVE LABOR DR (ES) | 2007-06-06 | — | — | CN | claimed |
| EP-1786419-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS (IN PARTICULAR CIZOLIRTIN CITRATE) FOR THE TREATMENT OF OPIOID ADDICTION | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1786420-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF CENTRAL NEUROPATHIC PAIN | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-04-19 | — | — | US | claimed |
| US-20070082893-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-12 | — | — | US | claimed |
| EP-1755678-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-28 | — | — | EP | claimed |
| EP-1746986-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-31 | — | — | EP | claimed |
| WO-2005097099-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A CARBINOL COMBINED TO AT LEAST AN NSAID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | claimed |
| WO-2005097192-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-20 | — | — | WO | claimed |
| EP-1584335-A2 | Active substance combination comprising a carbinol composition and an opioid | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-10-12 | — | — | EP | claimed |
| US-20050222136-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| US-20050222135-A1 | Active substance combination | LABORATIONS DEL DR. ESTEVE S.A. (ES) | 2005-10-06 | — | — | US | claimed |
| CN-1151789-C | Utilization of aryl (or heteroaryl) azolylcarbinol derivatives in prepn. of medicament for treating troubles mediated by excess of substance P | ��˹���IJ�ʿʵ���ҹɷ�����˾ | 2004-06-02 | — | — | CN | claimed |
| EP-1103243-B1 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | ESTEVE LABOR DR (ES) | 2004-01-07 | — | — | EP | claimed |
| CN-1317966-A | Use of derivatives of aryl (or heteroaryl) pyrrolylcarbinol for the manufacture of a medicament for the treatment of diseases mediated by an excess of substance P | ESTEVE LABOR DR (ES) | 2001-10-17 | — | — | CN | claimed |
| EP-1103243-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-05-30 | — | — | EP | claimed |
| EP-0289380-B1 | Aryl-heteroaryl-carbinol derivatives having an analgesic activity | ESTEVE LABOR DR (ES) | 1994-12-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222135-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | MAPT 2598/4885ALDH1A1 39/4885KMT2A 1439/4885 |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | PTGS1, PTGS2, PTGES2 | MAPT 3540/4885ALDH1A1 312/4885KMT2A 3087/4885 |
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | CNR2, CNR1, HCRTR2 | MAPT 2120/4885ALDH1A1 451/4885KMT2A 1689/4885 |
| US-20050222136-A1 | Active substance combination | PTGS1, MMP8, TACR1 | MAPT 3182/4885ALDH1A1 137/4885KMT2A 2783/4885 |
| US-20070082893-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | MAPT 2598/4885ALDH1A1 39/4885KMT2A 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.